Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based specialty biopharmaceutical company Shire has doubled its sales force in the US as part of its marketing efforts to increase the promotion of hyperactivity drugs to adults, reported the Financial Times.
Subscribe to our email newsletter
Shire has previously inked a deal with Glaxosmithkline (GSK) to co-promote Vyvanse, Shire’s new drug for the treatment of attention deficit and hyperactivity disorder. The agreement is expected to add 600 US sales representatives from GSK to Shire’s 600 employees working on the promotion of Vyvanse, reported the news source.
Shire believes that the combined sales force will help complement the promotion efforts of both the companies since GSK’s sale force is focusing primarily on adult specialists in the primary care sector while its sale force is targeting specialists in the pediatric area.